Comparison of the Pharmacokinetics and Pharmacodynamics of LY2963016 Insulin Glargine and EU- and US-Approved Versions of Lantus Insulin Glargine in Healthy Subjects: Three Randomized Euglycemic Clamp Studies
Article Information
vol. 38 no. 12 2226-2233
PubMed
Published By
Print ISSN
Online ISSN
History
- Received November 5, 2014
- Accepted July 21, 2015
- Published in print November 24, 2015.
- Published online ahead of print August 25, 2015.
Article Versions
- Previous version (August 25, 2015 - 13:51).
- You are viewing the most recent version of this article.
Copyright & Usage
© 2015 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.
Author Information
- Helle Linnebjerg1⇑,
- Eric Chen Quin Lam2,
- Mary E. Seger1,
- David Coutant1,
- Laiyi Chua2,
- Chew Lan Chong2,
- Maria M. Ferreira3,
- Danny Soon2 and
- Xin Zhang1
- 1Eli Lilly and Company, Indianapolis, IN
- 2Lilly-NUS Centre for Clinical Pharmacology, Singapore
- 3PAREXEL International Bloemfontein Early Phase Unit, Bloemfontein, South Africa
- Corresponding author: Helle Linnebjerg, linnebjerg_helle{at}lilly.com.
Statistics from Altmetric.com
Article usage
In this Issue
December 2015, 38(12)
Comparison of the Pharmacokinetics and Pharmacodynamics of LY2963016 Insulin Glargine and EU- and US-Approved Versions of Lantus Insulin Glargine in Healthy Subjects: Three Randomized Euglycemic Clamp Studies
